



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,431	08/24/2006	Yoshinori Sekiguchi	Q74854	1607
23373 7590 03/12/2010 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037				
EXAMINER TRUONG, TAMTHOM NGO				
ART UNIT		PAPER NUMBER		
1624				
NOTIFICATION DATE		DELIVERY MODE		
03/12/2010		ELECTRONIC		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

sughrue@sughrue.com  
PPROCESSING@SUGHRUE.COM  
USPTO@SUGHRUE.COM

# Office Action Summary

**Application No.**

10/551,431

**Applicant(s)**

SEKIGUCHI ET AL.

**Examiner**

TAMTHOM N. TRUONG

**Art Unit**

1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 11/02/09 (Election).
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-57 is/are pending in the application.
- 4a) Of the above claim(s) 10-33 and 35-47 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-9, 34 and 48-57 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date 2-26-10.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### DETAILED ACTION

Applicants' election with traverse of Group I in the response of 11/02/09 is acknowledged. Applicants have revised Group I to include claims 1-18, 34, 43, and 48-57, and also have elected the following species (on page 121):

The elected species reads on claims 1-9, 34 and 48-57. Claims 10-33 and 35-47 are held withdrawn as being drawn to the non-elected subject matter.

#### Example 3

**1-(2,6-Dichloro-phenyl)-3-[*cis*-4-(4-dimethylamino-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride**

Group I has been indicated with a further restriction, and thus, it is divided into two groups as below:

**Group Ia:** Claims 1-9, 34 and 48-57 (in part), drawn to compounds of Formula (I), and a pharmaceutical composition thereof, wherein:

- a. L represents groups IV, V, or VI;
- b. Y is group (i).

**Group Ib:** Claims 1-18, 34, 43 and 48-57 (in part), drawn to compounds of Formula (I) and a pharmaceutical composition thereof, wherein:

- a. L represents groups VII, VIII, IX, X or XI;
- b. Y is group (i).

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

1. Claims 1-9, 34 and 48-57 are rejected under 35 U.S.C. 102(b) as being anticipated by **Rüeger et. al.** (WO 97/20823). On page 82, Rüeger discloses on the last two lines, compound (d) which is *trans*-{4-[*(4-Amino-quinazolin-2-ylamino)-methyl*]-cyclohexylmethyl}-carbamic acid *tert-butyl ester*. The disclosed compound reads on some compound of formula I with the following substituents:

- i. Q is formula IIa;
- ii. R<sub>2</sub> is -N(R<sub>2a</sub>)(R<sub>2b</sub>), wherein R<sub>2a</sub> and R<sub>2b</sub> are hydrogen; or R<sub>2</sub> is -NH<sub>2</sub>.
- iii. X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> are hydrogen;
- iv. L is formula VI;
- v. A and B, each is -CH<sub>2</sub>-;
- vi. Y is -C(O)O-;
- vii. R<sub>1</sub> is an alkyl group (or t-butyl).

***Claim Rejections - 35 USC § 112, Second Paragraph***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1-9, 34 and 48-57 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:

- a. The structure of formula I shows variable  $R_1$  (subscripted), but the definition, shows variable  $R^1$  (superscripted). Thus, there is inconsistency between the structure and the claim content and/or disclosure.
- b. The definition of  $R^1$  includes "oxo" which is not rational because Y is a linking group of  $-C(O)NR_7$ ,  $-C(S)NR_7$  or  $-C(O)O-$ , and for  $R^1$  as an "oxo" group, the N or O would have improper valency.
- c. The specification does not provide a definition for "solvates" in term of appropriate solvents and proportion. Thus, it is unclear what constitutes a solvate of the instantly claimed compounds of the invention.
- d. Claims 49-51, 54 and 56 recite indications that counteract each other. For example, treating sleeping vs. arousal disorders, likewise treating obesity vs. bulimia/anorexia, also treating anxiety/depression.
- e. Claims 49, 50, 53 and 55 recite "eating disorders" which is a broad limitation, and also "obesity", "bulimia" and "anorexia" which are narrow limitations.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the

resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949).

### ***Claim Rejections - 35 USC § 112, First Paragraph***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. **Scope of Enablement:** Claims 1-16 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the preparation and use of *salts* and *hydrates*, does not reasonably provide enablement for the preparation and use of *solvates*. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The following factors have been considered in the determination of an enabling disclosure:

- (1) The breadth of the claims;
- (2) The amount of direction or guidance presented;
- (3) The state of the prior art;
- (4) The relative skill of those in the art;
- (5) The predictability or unpredictability of the art;
- (6) The quantity of experimentation necessary;

[See *Ex parte Forman*, 230 USPQ 546 (Bd. Pat. App. & Int., 1986); also *In re Wands*, 858 F. 2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)].

**The breadth of the claims:** Claims 1 and 15 recite the limitation of “solvate” of compounds represented by formula (I). The term “solvate” covers various forms of the same compound at different proportions of solvents. Thus, the scopes of claims 1 and 10 are unduly broad.

Claims 2-14 and 16 depend on claim 1, and thus, carry out the same broad scope of “solvate”.

**The amount of direction or guidance presented:** Although the specification lists possible salts and mentions “hydrates”, it does not define in full clear and exact terms, the identity of a solvate or how to prepare a “solvate” by providing guidance on what proportion of solvents to compounds may be used to obtain a “solvate”. Thus, the specification fails to provide sufficient enablement for making a “solvate” of the claimed compounds.

**The state of the prior art:** Although it is not unusual to expect a “solvate” of a compound, the process for selecting a solvent to make a solvate is not standard for all drugs since

not all solvents can form solvates with all compounds. For the claimed compound, there is no reference teaching any possible solvate. Furthermore, the teaching of Vippagunta states on page 18, section 3.4 the following:

"Predicting the formation of solvates or hydrates of a compound...is complex and difficult."

Thus, the state of the prior art does not support the broad scopes of claims 1 and 15.

**The relative skill of those in the art:** Even with the advanced training, the skilled clinician would have to engage in extensive research to select a "solvate" for each compound from the large Markush group of formula (I). Not only one has to determine an  $IC_{50}$  value, but also *in-vivo* activity to establish an  $LD_{50}$ , therapeutic index and active metabolites for each "solvate". Given a large Markush group of formula (I), such a task would require a tremendous amount of effort, time and resource.

**The predictability or unpredictability of the art & The quantity of experimentation necessary:** The process of making a "solvate" is quite unpredictable because it is not possible to predict whether solid solutions will form and at what stoichiometry proportion (i.e, one, two, or half a molecule of solvent added per molecule of host) – see the following excerpt of

**Vippagunta et. al. :**

Each solid compound responds uniquely to the possible formation of solvates...and hence generalizations cannot be made for a series of related compounds. Certain molecular shapes and features favor the formation of crystals without solvent;...There may be too many possibilities so that no computer programs are currently available for predicting the crystal structures of ...solvates.



(Vippagunta et. al., Crystalline solids, *Advanced Drug Delivery Review*, 48(2001) 3-26)

Thus, with such a limited teaching from the specification and the art, the skilled chemist would have to engage in undue experimentation to make the hundreds of thousands of compounds and "solvates" of compounds represented by formula (I) recited in claims 1 and 15.

-----  
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAMTHOM N. TRUONG whose telephone number is (571)272-0676. The examiner can normally be reached on M, T and Th (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tamthom N. Truong/  
Examiner, Art Unit 1624

/James O. Wilson/  
Supervisory Patent Examiner, Art Unit 1624

\*\*\*  
2-4-10